View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 27, 2019

FDA approves Regeneron’s antibody Dupixent for nasal polyposis

The US Food and Drug Administration (FDA) has approved Dupixent, a fully-human monoclonal antibody (mAb) that is being jointly developed by Regeneron Pharmaceuticals and Sanofi under a global collaboration agreement.

The US Food and Drug Administration (FDA) has approved Dupixent, a fully-human monoclonal antibody (mAb) that is being jointly developed by Regeneron Pharmaceuticals and Sanofi under a global collaboration agreement.

The approval is for the use of the antibody with other medicines to treat adults with chronic rhinosinusitis with nasal polyposis (CRSwNP). This chronic disease affects upper airways that obstruct the sinuses and nasal passages.

Dupixent is capable of hindering the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins, which play a key role in type 2 inflammation.

Clinical trials of Dupixent have shown that inhibiting IL-4 and IL-13 addresses the inflammation associated with CRSwNP, asthma and atopic dermatitis.

Regeneron Pharmaceuticals president and chief scientific officer George Yancopoulos said: “Dupixent is the first FDA-approved medicine for adults with chronic rhinosinusitis with nasal polyposis, and the only approved therapy shown to shrink nasal polyp size and also improve the signs and symptoms of the associated chronic rhinosinusitis.

“This approval further reinforces that IL-4 and IL-13 are key drivers of type 2 inflammation, and we continue to study Dupixent in other type 2 inflammatory diseases, including eosinophilic esophagitis and food and environmental allergies.”

The FDA’s approval was based on the 24-week SINUS-24 and 52-week SINUS-52 trials that are part of the Phase III LIBERTY clinical programme.

The studies saw the evaluation of 300mg of the drug alongside standard-of-care mometasone furoate nasal spray (MFNS) compared to placebo injection plus MFNS.

In these trials, Dupixent significantly improved key disease measures and met primary and secondary endpoints.

The drug is available in a 300mg pre-filled syringe for CRSwNP patients and is administered as a subcutaneous injection every other week at different injection sites.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology